Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
| 958000 | |
| 941000 | |
| - | |
| 960000 | |
| 933000 | |
| 698000-999999.9999 | |
| 68 184 690 M | |
| 71 174 K | |
| 4 211 290 M | |
| 3716 | |
| 0.323 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation The platform can address challenges associated with viscosity and achieve stable liquid formulation...
Samsung Biologics showcases new innovative development platforms – S-AfuCHOTM and S-OptiChargeTM – at BioProcess International 2024 New technology platforms to proactively address evolving industr...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
